1-855-RxRxCSS / 1-855-797-9277

Clinical Trials

print-iconemail-iconshare-icon

As part of our mission to deliver the latest medical breakthroughs, the Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network physicians conduct clinical trials that test new treatments for different patients and cancer types. The following trials are coming soon to Chan Soon-Shiong Institute for Medicine at Mariposa.

Open-label, Phase 1 Study of haNKĀ® for Infusion in Subjects With Metastatic or
Locally Advanced Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT03027128
Indication: Solid Tumors
NCT03027128 | QUILT-3.028


NANT Pancreatic Cancer Vaccine™: Molecularly Informed Integrated Immunotherapy
in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

https://www.clinicaltrials.gov/ct2/show/NCT03387098
Indication: Pancreatic cancer
NCT03387098 | QUILT-3.070


NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with TNBC Who Have Progressed on or After Standard-of-care Therapy
https://clinicaltrials.gov/ct2/show/NCT03387085
Indication: Triple Negative Breast Cancer
NCT03387085 | QUILT-3.067


NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy
https://clinicaltrials.gov/ct2/show/NCT03387111
Indication: Squamous Cell Carcinoma
NCT03387111 | QUILT-3.090


A Phase 1 Trial of ABI-011 Administered Weekly in Patients with Advanced Solid Tumors or Lymphomas
https://clinicaltrials.gov/ct2/show/NCT02582827
Indication: Solid Tumors and Lymphomas
NCT02582827 | QUILT-3.014


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Clear Cell Sarcoma that Contains the EWSR1-ATF1 Gene Fusion
https://clinicaltrials.gov/ct2/show/NCT03132155
Indication: Clear Cell Sarcoma
NCT03132155 | QUILT-3.031


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Solid Tumors that Overexpress MET or Harbor MET EXON 14Skipping (METEX14DEL) Mutations
https://clinicaltrials.gov/ct2/show/NCT03147976
Indication: Solid Tumors
NCT03147976 | Quilt-3.036

For More Information

1-855-RxRxCSS

1-855-797-9277

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa
2040 East Mariposa Avenue
El Segundo, California 90245

We are not currently accepting walk-ins. Please call to schedule an appointment.

For More Information

1-855-RxRxCSS

1-855-797-9277

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa
2040 East Mariposa Avenue
El Segundo, California 90245

We are not currently accepting walk-ins. Please call to schedule an appointment.